Interleukin 1 (IL1) - Pipeline Review, H2 2018
Interleukin 1 (IL1) - Pipeline Review, H2 2018
SUMMARY
Interleukin 1 (IL1) - Interleukin-1 is a cytokine which plays an important role regulation of immune and inflammatory responses. It helps leukocytes pass through blood vessel walls to sites of infection and causes fever by affecting areas of the brain that control body temperature. There are two forms of interleukin-1, alpha and beta. IL-1 stimulates thymocyte proliferation by inducing IL-2 release, B-cell maturation and proliferation, and fibroblast growth factor activity.
Interleukin 1 (IL1) pipeline Target constitutes close to 18 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 5, 1, 7 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Immunology, Cardiovascular, Oncology, Dermatology, Gastrointestinal, Metabolic Disorders, Musculoskeletal Disorders, Ear Nose Throat Disorders, Genetic Disorders, Central Nervous System, Genito Urinary System And Sex Hormones and Hematological Disorders which include indications Gouty Arthritis (Gout), Inflammation, Non-Small Cell Lung Cancer, Acne Vulgaris, Atopic Dermatitis (Atopic Eczema), Behcet Disease, Type 2 Diabetes, Arterial Thrombosis, Atherosclerosis, Autoimmune Disorders, Bullous Pemphigoid, Cancer Anorexia-Cachexia Syndrome, Cardiovascular Risk Factors, Cholangitis, Colorectal Cancer, Epidermolysis Bullosa, Esophageal Cancer, Fallopian Tube Cancer, Familial Mediterranean Fever, Hearing Disorders, Hidradenitis Suppurativa, Inflammatory Bowel Disease, Kidney Fibrosis, Limited/Distal Colitis, Liver Fibrosis, Lymphoma, Metastatic Colorectal Cancer, Muckle-Wells Syndrome, Myocardial Infarction, Neonatal Onset Multisystem Inflammatory Disease, Ovarian Cancer, Pain, Pancreatic Cancer, Pericarditis, Plaque Psoriasis (Psoriasis Vulgaris), Prostate Cancer, Psoriasis, Restenosis, Rheumatoid Arthritis, Rhinitis, Sarcoidosis, Sickle Cell Disease, Skin Ulcers and Squamous Non-Small Cell Lung Cancer.
The latest report Interleukin 1 - Pipeline Review, H2 2018, outlays comprehensive information on the Interleukin 1 (IL1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Interleukin 1 (IL1) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Interleukin 1 (IL1) - Interleukin-1 is a cytokine which plays an important role regulation of immune and inflammatory responses. It helps leukocytes pass through blood vessel walls to sites of infection and causes fever by affecting areas of the brain that control body temperature. There are two forms of interleukin-1, alpha and beta. IL-1 stimulates thymocyte proliferation by inducing IL-2 release, B-cell maturation and proliferation, and fibroblast growth factor activity.
Interleukin 1 (IL1) pipeline Target constitutes close to 18 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 5, 1, 7 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Immunology, Cardiovascular, Oncology, Dermatology, Gastrointestinal, Metabolic Disorders, Musculoskeletal Disorders, Ear Nose Throat Disorders, Genetic Disorders, Central Nervous System, Genito Urinary System And Sex Hormones and Hematological Disorders which include indications Gouty Arthritis (Gout), Inflammation, Non-Small Cell Lung Cancer, Acne Vulgaris, Atopic Dermatitis (Atopic Eczema), Behcet Disease, Type 2 Diabetes, Arterial Thrombosis, Atherosclerosis, Autoimmune Disorders, Bullous Pemphigoid, Cancer Anorexia-Cachexia Syndrome, Cardiovascular Risk Factors, Cholangitis, Colorectal Cancer, Epidermolysis Bullosa, Esophageal Cancer, Fallopian Tube Cancer, Familial Mediterranean Fever, Hearing Disorders, Hidradenitis Suppurativa, Inflammatory Bowel Disease, Kidney Fibrosis, Limited/Distal Colitis, Liver Fibrosis, Lymphoma, Metastatic Colorectal Cancer, Muckle-Wells Syndrome, Myocardial Infarction, Neonatal Onset Multisystem Inflammatory Disease, Ovarian Cancer, Pain, Pancreatic Cancer, Pericarditis, Plaque Psoriasis (Psoriasis Vulgaris), Prostate Cancer, Psoriasis, Restenosis, Rheumatoid Arthritis, Rhinitis, Sarcoidosis, Sickle Cell Disease, Skin Ulcers and Squamous Non-Small Cell Lung Cancer.
The latest report Interleukin 1 - Pipeline Review, H2 2018, outlays comprehensive information on the Interleukin 1 (IL1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Interleukin 1 (IL1) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Interleukin 1 (IL1)
- The report reviews Interleukin 1 (IL1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Interleukin 1 (IL1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Interleukin 1 (IL1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Interleukin 1 (IL1) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Interleukin 1 (IL1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Interleukin 1 (IL1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Interleukin 1 (IL1) - Overview
Interleukin 1 (IL1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Interleukin 1 (IL1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Interleukin 1 (IL1) - Companies Involved in Therapeutics Development
Apexigen Inc
Link Health Group
Moderna Therapeutics Inc
Novartis AG
Omnitura Therapeutics Inc
Opsona Therapeutics Ltd
Peptinov SAS
R Pharm
Regeneron Pharmaceuticals Inc
Spherium Biomed SL
Swedish Orphan Biovitrum AB
XBiotech Inc
Interleukin 1 (IL1) - Drug Profiles
AC-203 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APX-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bermekimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
canakinumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
diacerein - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
diacerein CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LH-026 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
melittin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit IL-1a for Atherosclerosis and Myocardial Infarction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mRNA-2752 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMN-54 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PPV-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PUR-0110 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rilonacept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RPH-104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Interleukin 1 Beta for Muckle-Wells Syndrome, Neonatal Onset Multisystem Inflammatory Disease and Gouty Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SOBI-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SP-15008 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Interleukin 1 (IL1) - Dormant Products
Interleukin 1 (IL1) - Discontinued Products
Interleukin 1 (IL1) - Product Development Milestones
Featured News & Press Releases
Oct 26, 2018: XBiotech announces new patents for bermekimab in the third quarter of 2018
Oct 22, 2018: TWi Biotechnology enrols first patient in Phase II AC-203 trial
Oct 05, 2018: Xbiotech announces enrollment completion in phase 2 multicenter study evaluating Bermekimab in patients with atopic dermatitis
Sep 26, 2018: XBiotech announces granting of European patent for treatment of inflammatory skin diseases
Sep 24, 2018: XBiotech Announces Completion of U.S. Enrollment in Phase 2 Multicenter Study Evaluating Bermekimab in Patients with Hidradenitis Suppurativa
Sep 20, 2018: XBiotech announces addition of top dermatologist and researcher Dr. Alice Gottlieb to its team
Sep 13, 2018: XBiotech Announces Completion and Positive Interim Findings for Initial Cohort in Bermekimab Pilot Study in Atopic Dermatitis
Aug 27, 2018: Xbiotech announces publication of breakthrough findings for potential role of interleukin-1 alpha in risk for heart attacks
Aug 09, 2018: Castle Creek Pharmaceuticals receives FDA Fast Track Designation for Diacerein 1% ointment for treatment of Epidermolysis Bullosa Simplex
Jul 10, 2018: XBiotech Announces First Patient in Phase 2 Study Evaluating Subcutaneous MABp1 in Patients with Hidradenitis Suppurativa
Jun 25, 2018: Castle Creek Pharmaceuticals Announces First Patient with Epidermolysis Bullosa Enrolled in Pharmacokinetics Study of Diacerein 1% Ointment
Jun 22, 2018: Regeneron Regarding Royalty Agreement with Novartis for Canakinumab
May 22, 2018: XBiotech Announces First Patient in Phase 2 Study Evaluating MABp1 in Patients with Atopic Dermatitis
May 16, 2018: Castle Creek Pharmaceuticals Receives FDA Rare Pediatric Disease Designation for Diacerein 1% Ointment for Epidermolysis Bullosa
May 15, 2018: European Society of Cardiology consensus statement on inflammation in atherosclerosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Interleukin 1 (IL1) - Overview
Interleukin 1 (IL1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Interleukin 1 (IL1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Interleukin 1 (IL1) - Companies Involved in Therapeutics Development
Apexigen Inc
Link Health Group
Moderna Therapeutics Inc
Novartis AG
Omnitura Therapeutics Inc
Opsona Therapeutics Ltd
Peptinov SAS
R Pharm
Regeneron Pharmaceuticals Inc
Spherium Biomed SL
Swedish Orphan Biovitrum AB
XBiotech Inc
Interleukin 1 (IL1) - Drug Profiles
AC-203 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APX-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bermekimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
canakinumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
diacerein - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
diacerein CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LH-026 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
melittin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit IL-1a for Atherosclerosis and Myocardial Infarction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mRNA-2752 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMN-54 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PPV-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PUR-0110 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rilonacept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RPH-104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Interleukin 1 Beta for Muckle-Wells Syndrome, Neonatal Onset Multisystem Inflammatory Disease and Gouty Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SOBI-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SP-15008 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Interleukin 1 (IL1) - Dormant Products
Interleukin 1 (IL1) - Discontinued Products
Interleukin 1 (IL1) - Product Development Milestones
Featured News & Press Releases
Oct 26, 2018: XBiotech announces new patents for bermekimab in the third quarter of 2018
Oct 22, 2018: TWi Biotechnology enrols first patient in Phase II AC-203 trial
Oct 05, 2018: Xbiotech announces enrollment completion in phase 2 multicenter study evaluating Bermekimab in patients with atopic dermatitis
Sep 26, 2018: XBiotech announces granting of European patent for treatment of inflammatory skin diseases
Sep 24, 2018: XBiotech Announces Completion of U.S. Enrollment in Phase 2 Multicenter Study Evaluating Bermekimab in Patients with Hidradenitis Suppurativa
Sep 20, 2018: XBiotech announces addition of top dermatologist and researcher Dr. Alice Gottlieb to its team
Sep 13, 2018: XBiotech Announces Completion and Positive Interim Findings for Initial Cohort in Bermekimab Pilot Study in Atopic Dermatitis
Aug 27, 2018: Xbiotech announces publication of breakthrough findings for potential role of interleukin-1 alpha in risk for heart attacks
Aug 09, 2018: Castle Creek Pharmaceuticals receives FDA Fast Track Designation for Diacerein 1% ointment for treatment of Epidermolysis Bullosa Simplex
Jul 10, 2018: XBiotech Announces First Patient in Phase 2 Study Evaluating Subcutaneous MABp1 in Patients with Hidradenitis Suppurativa
Jun 25, 2018: Castle Creek Pharmaceuticals Announces First Patient with Epidermolysis Bullosa Enrolled in Pharmacokinetics Study of Diacerein 1% Ointment
Jun 22, 2018: Regeneron Regarding Royalty Agreement with Novartis for Canakinumab
May 22, 2018: XBiotech Announces First Patient in Phase 2 Study Evaluating MABp1 in Patients with Atopic Dermatitis
May 16, 2018: Castle Creek Pharmaceuticals Receives FDA Rare Pediatric Disease Designation for Diacerein 1% Ointment for Epidermolysis Bullosa
May 15, 2018: European Society of Cardiology consensus statement on inflammation in atherosclerosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Apexigen Inc, H2 2018
Pipeline by Link Health Group, H2 2018
Pipeline by Moderna Therapeutics Inc, H2 2018
Pipeline by Novartis AG, H2 2018
Pipeline by Omnitura Therapeutics Inc, H2 2018
Pipeline by Opsona Therapeutics Ltd, H2 2018
Pipeline by Peptinov SAS, H2 2018
Pipeline by R Pharm, H2 2018
Pipeline by Regeneron Pharmaceuticals Inc, H2 2018
Pipeline by Spherium Biomed SL, H2 2018
Pipeline by Swedish Orphan Biovitrum AB, H2 2018
Pipeline by XBiotech Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Dormant Products, H2 2018 (Contd.2), H2 2018
Dormant Products, H2 2018 (Contd.3), H2 2018
Dormant Products, H2 2018 (Contd.4), H2 2018
Dormant Products, H2 2018 (Contd.5), H2 2018
Discontinued Products, H2 2018
Discontinued Products, H2 2018 (Contd.1), H2 2018
Discontinued Products, H2 2018 (Contd.2), H2 2018
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Apexigen Inc, H2 2018
Pipeline by Link Health Group, H2 2018
Pipeline by Moderna Therapeutics Inc, H2 2018
Pipeline by Novartis AG, H2 2018
Pipeline by Omnitura Therapeutics Inc, H2 2018
Pipeline by Opsona Therapeutics Ltd, H2 2018
Pipeline by Peptinov SAS, H2 2018
Pipeline by R Pharm, H2 2018
Pipeline by Regeneron Pharmaceuticals Inc, H2 2018
Pipeline by Spherium Biomed SL, H2 2018
Pipeline by Swedish Orphan Biovitrum AB, H2 2018
Pipeline by XBiotech Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Dormant Products, H2 2018 (Contd.2), H2 2018
Dormant Products, H2 2018 (Contd.3), H2 2018
Dormant Products, H2 2018 (Contd.4), H2 2018
Dormant Products, H2 2018 (Contd.5), H2 2018
Discontinued Products, H2 2018
Discontinued Products, H2 2018 (Contd.1), H2 2018
Discontinued Products, H2 2018 (Contd.2), H2 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
Apexigen Inc
Link Health Group
Moderna Therapeutics Inc
Novartis AG
Omnitura Therapeutics Inc
Opsona Therapeutics Ltd
Peptinov SAS
R Pharm
Regeneron Pharmaceuticals Inc
Spherium Biomed SL
Swedish Orphan Biovitrum AB
XBiotech Inc
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
Apexigen Inc
Link Health Group
Moderna Therapeutics Inc
Novartis AG
Omnitura Therapeutics Inc
Opsona Therapeutics Ltd
Peptinov SAS
R Pharm
Regeneron Pharmaceuticals Inc
Spherium Biomed SL
Swedish Orphan Biovitrum AB
XBiotech Inc
